Item 7.01 Regulation FD Disclosure.
On April 1, 2020, NeuBase Therapeutics, Inc. (the "Company"), updated its
corporate presentation materials to include information from its webcasted
conference call held on March 31, 2020 and the target milestones of its two lead
programs utilizing its PATrOL™ platform: the NT0100 Program focused on the
treatment of Huntington's Disease and the NT0200 Program focused on the
treatment of Myotonic Dystrophy Type 1. A copy of the updated corporate
presentation materials referred to in this Item 7.01 of Current Report on Form
8-K (this "Current Report") is furnished herewith as Exhibit 99.1 to this
Current Report and incorporated herein by reference.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This Current Report contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act. These forward-looking statements
include, among other things, statements regarding the Company's target
milestones for its two lead programs. These views involve risks and
uncertainties that are difficult to predict and, accordingly, our actual results
may differ materially from the results discussed in our forward-looking
statements.
Our forward-looking statements contained herein speak only as of the date of
this Current Report. Factors or events that we cannot predict, including those
described in the risk factors contained in our filings with the U.S. Securities
and Exchange Commission, may cause our actual results to differ from those
expressed in forward-looking statements. The Company may not actually achieve
the plans, carry out the intentions or meet the expectations or projections
disclosed in the forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Because such statements deal with
future events and are based on the Company's current expectations, they are
subject to various risks and uncertainties and actual results, performance or
achievements of the Company could differ materially from those described in or
implied by the statements in this Current Report, including: the Company's plans
to develop and commercialize its product candidates; the Company's plans to
commence clinical trials in Huntington's disease and myotonic dystrophy type 1
and to potentially expand the pipeline into other indications; the utility of
the preclinical data generated in existing studies performed by the Company in
determining the results of potential future clinical trials and of the potential
benefits of the PATrOL™ platform technology; the timing of initiation of the
Company's planned clinical trials; the timing of the availability of data from
the Company's clinical trials; the timing of any planned investigational new
drug application or new drug application; the Company's plans to research,
develop and commercialize its current and potential future product candidates;
the clinical utility, potential benefits and market acceptance of the Company's
current and potential future product candidates; the Company's
commercialization, marketing and manufacturing capabilities and strategy; global
health conditions, including the impact of COVID-19; the Company's ability to
protect its intellectual property position; and the requirement for additional
capital to continue to advance these product candidates, which may not be
available on favorable terms or at all, as well as those risk factors in our
filings with the U.S. Securities and Exchange Commission. Except as otherwise
required by law, the Company disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the date hereof,
whether as a result of new information, future events or circumstances or
otherwise.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Corporate Presentation Materials.
© Edgar Online, source Glimpses